UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 15, 2008
HELICOS BIOSCIENCES CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware |
| 001-33484 |
| 05-0587367 |
(State or Other Jurisdiction |
| (Commission File Number) |
| (IRS Employer |
|
|
|
|
|
One Kendall Square |
| 02139 | ||
(Address of Principal Executive Offices) |
| (Zip Code) | ||
(617) 264-1800
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Item 7.01 Regulation FD Disclosure
Helicos BioSciences Corporation (“Helicos” or the “Company”) is preparing to place a HelicosTM Genetic Analysis System (“System”) at The Broad Institute (the “Broad”). The System will be provided to the Broad at no cost and is expected to be delivered and installed in early 2009.
Based on recent improvements to the Company’s single molecule sequencing chemistry and other System improvements, as of December 2008, the System has been shown to be capable of achieving sequencing performance in the range of approximately 100-140 megabases per hour with DNA samples, median read lengths of 33 bases and approximate total error rates of 5% (0.5% substitution error rate).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HELICOS BIOSCIENCES CORPORATION | |
|
| |
|
| |
| By: | /s/ Ronald A. Lowy |
Date: December 15, 2008 | Name: Ronald A. Lowy | |
| Title: Chief Executive Officer | |
3